Please login to the form below

Not currently logged in
Email:
Password:

inflammatory conditions

This page shows the latest inflammatory conditions news and features for those working in and with pharma, biotech and healthcare.

WHO recommends ‘life-saving’ IL-6 inhibitors for severe COVID-19

WHO recommends ‘life-saving’ IL-6 inhibitors for severe COVID-19

Both Actemra and Kevzara are IL-6 receptor agonists and are most commonly used to treat anti-inflammatory conditions, including arthritis. ... IL-6 is thought to play a role in driving the overactive inflammatory response in the lungs of critically and

Latest news

  • Novartis agrees to help produce Roche’s repurposed COVID-19 drug Novartis agrees to help produce Roche’s repurposed COVID-19 drug

    Actemra/RoActemra (tocilizumab) is already approved to treat a number of inflammatory conditions, including rheumatoid arthritis, paediatric juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, giant cell arteritis and CAR-T

  • FDA approves new self-injection administration for Xolair FDA approves new self-injection administration for Xolair

    This includes a number of allergic and inflammatory conditions, including moderate-to-severe persistent allergic asthma, chronic idiopathic urticaria (CIU) and nasal polyps. ... Today's approval reflects our commitment to continued innovation with

  • Two drugs found to reduce mortality in severe COVID-19 patients Two drugs found to reduce mortality in severe COVID-19 patients

    Both Actemra and Kevzara are IL-6 receptor agonists and are most commonly used to treat anti-inflammatory conditions, including arthritis. ... IL-6 is thought to play a role in driving the overactive inflammatory response in the lungs of critically and

  • World Castleman Disease Day World Castleman Disease Day

    The symptoms of iMCD are often attributed to other, more well-known conditions. ... Patients can experience inflammatory symptoms such as enlarged lymph nodes, weight loss, fatigue and fever.

  • Lilly cuts deal with UK’s Sitryx for autoimmune disease drugs Lilly cuts deal with UK’s Sitryx for autoimmune disease drugs

    At the time the biotech said it would focus on potential therapies for cancer and autoimmune conditions, with its operations supported by GSK’s drug discovery capabilities. ... in autoimmune and inflammatory conditions.

More from news
Approximately 0 fully matching, plus 37 partially matching documents found.

Latest Intelligence

  • Setting up for success in a post-Brexit, post-pandemic Britain Setting up for success in a post-Brexit, post-pandemic Britain

    However, we must not neglect the fact that, for non-COVID patients, many people have faced delays and cancellations for the treatment of debilitating conditions, such as Inflammatory Bowel Disease (IBD) ... With a focus on inflammatory and fibrotic

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    conditions. 2. AR101 – the first peanut allergy treatment. Potentially deadly allergies to food and other everyday substances are on the rise around the world – and there are currently very few therapies ... Boehringer Ingelheim) for psoriatic

  • Medius Deal Watch table for April 2015 Medius Deal Watch table for April 2015

    49. Mesoblast / Celgene. Minority investment and option to license. stem-cell product candidates for conditions including inflammatory bowel disease and certain oncological indications.

  • Pharma deals in April 2015 Pharma deals in April 2015

    Celgene, will gain six months right of first refusal on Mesoblast's stem-cell product candidates for conditions including inflammatory bowel disease and certain oncological indications, for global rights (excluding Japan),

  • Deal Watch table for April 2014 Deal Watch table for April 2014

    7, 100. Questcor/ Mallinckrodt. Acquisition. Acthar Gel (repository corticotropin) for “difficult-to-treat” autoimmune/ inflammatory conditions.

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...